[Clinical evaluation of combination therapy with sulbactam/cefoperazone and amikacin sulfate for infections associated with hematological disorders].
We evaluated the efficacy and safety of combination therapy with sulbactam/cefoperazone (SBT/CPZ) and amikacin sulfate (AMK) in severe infections associated with hematological disorders. The clinical efficacy rate in 82 evaluable patients was 70.7%. The efficacy rate in sepsis from which causative organisms were isolated was high, 75% (3/4). No significant difference was found between those cases for which no previous antibiotic therapies were made and those for which antibiotic therapies were done and changed to the combination during the course of the therapies. No side effects nor substantial abnormal laboratory test results attributable to the test drugs were observed. From these observations, we have concluded that the combination therapy with SBT/CPZ plus AMK is a very useful empiric therapy for severe infections associated with hematological disorders.
Fukuda
M
M
First Department of Internal Medicine, Saitama Medical School.
Hirashima
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002438:Cefoperazone / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013407:Sulbactam / Q000008:administration & dosage
D002438:Cefoperazone; D000583:Amikacin; D013407:Sulbactam